Background:
Cancer stem cells (CSC) are subpopulation within the tumor that acts a part in the initiation, progression,
recurrence, resistance to drugs and metastasis of cancer. It is well known that epigenetic changes lead to tumor formation in cancer stem
cells and show drug resistance. Epigenetic modulators and /or their combination with different agents have been used in cancer therapy.
Objective:
In our study we scope out the effects of combination of a histone deacetylases inhibitor, valproic acid (VPA), and Cu(II)
complex [Cu(barb-κN)(barb-κ2N,O)(phen-κN,N’)]·H2O] on cytotoxicity/apoptosis in a stem-cell enriched population (MCF-7s) obtained
from parental breast cancer cell line (MCF-7).
Methods:
Viability of the cells was measured by the ATP assay. Apoptosis was elucidated via the assessment of caspase-cleaved
cytokeratin 18 (M30 ELISA) and a group of flow cytometry analysis (caspase 3/7 activity, phosphatidylserine translocation by annexin
V-FITC assay, DNA damage and oxidative stress) and 2ˈ,7ˈ–dichlorofluorescein diacetate staining.
Results:
The VPA combined with Cu(II) complex showed anti proliferative activity on MCF-7s cells in a dose- and time-dependently.
Treatment with combination of 2.5 mM VPA and 3.12 μM Cu(II) complex induces oxidative stress in a time-dependent manner, as well
as apoptosis that is evidenced by the increase in caspase 3/7 activity, positive annexin-V-FITC, and increase in M30 levels.
Conclusion:
The results suggest that the combination therapy induces apoptosis following increased oxidative stress, thereby making it a
possible promising therapeutic strategy that further analysis is required.
Antioxidants for the Treatment of Breast Cancer: Are We There Yet?
